Join
Live feed
·
PRReleasevia Quantisnow
Ventyx Biosciences Inc. logo

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

ByQuantisnow·Wall Street's wire, on your screen.
VTYX· Ventyx Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTYX (Ventyx Biosciences Inc.) and more on Quantisnow.